In the News
TwinStrand Biosciences has announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives. As part of this effort, TwinStrand has named Chad Brown as interim Chief Executive Officer, while TwinStrand founder, Jesse Salk, MD, PhD, will continue to serve the company as Chief Scientific Officer.
Our CEO, Jesse Salk MD, PhD will be speaking at the Life Sciences Innovation Northwest (LSINW) 2022 Convention during the Research Tools & Medical Device session.
Wednesday, April 20th, 2022 – 2:46pm PST
An Interview with Jesse Salk, MD, PhD, CEO of TwinStrand Biosciences
This year we were proud to sponsor the scientific workshop Applying Molecular Biology & Genetic Toxicology Methods to Improve Risk Assessment and Guide Risk Management Decisions for Cancer in Firefighters at the 2022 National Cancer Fire Symposium, hosted by the Firefighter Cancer Initiative (FCI).
TwinStrand Biosciences, Inc. was selected to join the FNIH Biomarkers Consortium Project aiming to establish new methods for detecting measurable residual disease (MRD) in Acute Myeloid Leukemia (AML). See the FNIH announcement here.
